BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Corti F, Nichetti F, Raimondi A, Niger M, Prinzi N, Torchio M, Tamborini E, Perrone F, Pruneri G, Di Bartolomeo M, de Braud F, Pusceddu S. Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives. Cancer Treat Rev 2019;72:45-55. [PMID: 30476750 DOI: 10.1016/j.ctrv.2018.11.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 44] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Sharma V, Sharma AK, Punj V, Priya P. Recent nanotechnological interventions targeting PI3K/Akt/mTOR pathway: A focus on breast cancer. Semin Cancer Biol 2019;59:133-46. [PMID: 31408722 DOI: 10.1016/j.semcancer.2019.08.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
2 Taghizadeh H, Müllauer L, Mader R, Prager GW. Applied precision cancer medicine in metastatic biliary tract cancer. Hepatol Int 2020;14:288-95. [PMID: 32100259 DOI: 10.1007/s12072-020-10020-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Yan G, Wang J, Yi T, Cheng J, Guo H, He Y, Shui X, Wu Z, Huang S, Lei W. Baicalin prevents pulmonary arterial remodeling in vivo via the AKT/ERK/NF-κB signaling pathways. Pulm Circ 2019;9:2045894019878599. [PMID: 31723406 DOI: 10.1177/2045894019878599] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Acharya B, Chaijaroenkul W, Na-Bangchang K. Atractylodin inhibited the migration and induced autophagy in cholangiocarcinoma cells via PI3K/AKT/mTOR and p38MAPK signalling pathways. J Pharm Pharmacol 2021:rgab036. [PMID: 33885818 DOI: 10.1093/jpp/rgab036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Pant K, Richard S, Peixoto E, Gradilone SA. Role of Glucose Metabolism Reprogramming in the Pathogenesis of Cholangiocarcinoma. Front Med (Lausanne) 2020;7:113. [PMID: 32318579 DOI: 10.3389/fmed.2020.00113] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
6 Zhang S, Xie Y, Tian T, Yang Q, Zhou Y, Qiu J, Xu L, Wen N, Lv Q, Du Z. High expression levels of centromere protein A plus upregulation of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling pathway affect chemotherapy response and prognosis in patients with breast cancer. Oncol Lett 2021;21:410. [PMID: 33841571 DOI: 10.3892/ol.2021.12671] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Park SR, Kim SR, Hong IS, Lee HY. A Novel Therapeutic Approach for Colorectal Cancer Stem Cells: Blocking the PI3K/Akt Signaling Axis With Caffeic Acid. Front Cell Dev Biol 2020;8:585987. [PMID: 33425893 DOI: 10.3389/fcell.2020.585987] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Chamcheu JC, Roy T, Uddin MB, Banang-Mbeumi S, Chamcheu RN, Walker AL, Liu YY, Huang S. Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy. Cells 2019;8:E803. [PMID: 31370278 DOI: 10.3390/cells8080803] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 15.7] [Reference Citation Analysis]
9 Feng YQ, Gu SX, Chen YS, Gao XD, Ren YX, Chen JC, Lu YY, Zhang H, Cao S. Virtual Screening and Optimization of Novel mTOR Inhibitors for Radiosensitization of Hepatocellular Carcinoma. Drug Des Devel Ther 2020;14:1779-98. [PMID: 32440103 DOI: 10.2147/DDDT.S249156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
10 Chiang NJ, Chen LT, Shan YS, Yeh CN, Chen MH. Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials. Biomolecules 2021;11:97. [PMID: 33451059 DOI: 10.3390/biom11010097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Li C, Liang G, Yang S, Sui J, Wu W, Xu S, Ye Y, Shen B, Zhang X, Zhang Y. LncRNA-LOC101928316 contributes to gastric cancer progression through regulating PI3K-Akt-mTOR signaling pathway. Cancer Med 2019;8:4428-40. [PMID: 31207155 DOI: 10.1002/cam4.2165] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
12 Cheng Q, Li Y, Guo X, Li H. Involvement of mTOR/Survivin signaling pathway in TUA(2β, 3β, 23-trihydroxy-urs-12-ene-28-olic acid)-induced apoptosis in human gastric cancer cell line BGC823 cells. J Ethnopharmacol 2021;267:113437. [PMID: 33011370 DOI: 10.1016/j.jep.2020.113437] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Wang Z, Yang X, Gui S, Yang F, Cao Z, Cheng R, Xia X, Li C. The Roles and Mechanisms of lncRNAs in Liver Fibrosis. Front Pharmacol 2021;12:779606. [PMID: 34899344 DOI: 10.3389/fphar.2021.779606] [Reference Citation Analysis]
14 Xu T, Rao T, Yu WM, Ning JZ, Yu X, Zhu SM, Yang K, Bai T, Cheng F. Upregulation of NFKBIZ affects bladder cancer progression via the PTEN/PI3K/Akt signaling pathway. Int J Mol Med 2021;47:109. [PMID: 33907827 DOI: 10.3892/ijmm.2021.4942] [Reference Citation Analysis]
15 He R, Xu B, Ping L, Lv X. Structural optimization towards promising β-methyl-4-acrylamido quinoline derivatives as PI3K/mTOR dual inhibitors for anti-cancer therapy: The in vitro and in vivo biological evaluation. Eur J Med Chem 2021;214:113249. [PMID: 33561608 DOI: 10.1016/j.ejmech.2021.113249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Li Y, Sun Q, Li H, Yang B, Wang M. Vitexin suppresses renal cell carcinoma by regulating mTOR pathways. Transl Androl Urol 2020;9:1700-11. [PMID: 32944531 DOI: 10.21037/tau-20-1094] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
17 Yang W, Sun Y. Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview. Onco Targets Ther 2021;14:1341-66. [PMID: 33658799 DOI: 10.2147/OTT.S297643] [Reference Citation Analysis]
18 Casadio M, Biancaniello F, Overi D, Venere R, Carpino G, Gaudio E, Alvaro D, Cardinale V. Molecular Landscape and Therapeutic Strategies in Cholangiocarcinoma: An Integrated Translational Approach towards Precision Medicine. Int J Mol Sci 2021;22:5613. [PMID: 34070643 DOI: 10.3390/ijms22115613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Li C, Wang Q, Wang X, Li G, Shen S, Wei X. Scutellarin inhibits the invasive potential of malignant melanoma cells through the suppression epithelial-mesenchymal transition and angiogenesis via the PI3K/Akt/mTOR signaling pathway. European Journal of Pharmacology 2019;858:172463. [DOI: 10.1016/j.ejphar.2019.172463] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
20 Lu ZN, Song J, Sun TH, Sun G. UBE2C affects breast cancer proliferation through the AKT/mTOR signaling pathway. Chin Med J (Engl) 2021;134:2465-74. [PMID: 34620747 DOI: 10.1097/CM9.0000000000001708] [Reference Citation Analysis]
21 Canale M, Monti M, Rapposelli IG, Ulivi P, Sullo FG, Bartolini G, Tiberi E, Frassineti GL. Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer. Cancers (Basel) 2021;13:5671. [PMID: 34830826 DOI: 10.3390/cancers13225671] [Reference Citation Analysis]
22 Li YX, Ding SS, Wen WJ, Han L, Wang HQ, Shi HY. Impact of the Activation Status of the Akt/mTOR Signalling Pathway on the Clinical Behaviour of Synovial Sarcoma: Retrospective Analysis of 174 Patients at a Single Institution. Cancer Manag Res 2020;12:1759-69. [PMID: 32210617 DOI: 10.2147/CMAR.S228578] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Mu Q, Najafi M. Modulation of the tumor microenvironment (TME) by melatonin. Eur J Pharmacol 2021;907:174365. [PMID: 34302814 DOI: 10.1016/j.ejphar.2021.174365] [Reference Citation Analysis]
24 Shen J, Zhou Y, Zhang X, Peng W, Peng C, Zhou Q, Li C, Wen T, Shi Y. Loss of FoxA2 accelerates neoplastic changes in the intrahepatic bile duct partly via the MAPK signaling pathway. Aging (Albany NY) 2019;11:9280-94. [PMID: 31689237 DOI: 10.18632/aging.102332] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Xu M, Zhang X, Zhang S, Piao J, Yang Y, Wang X, Lin Z. SPOCK1/SIX1axis promotes breast cancer progression by activating AKT/mTOR signaling. Aging (Albany NY) 2020;13:1032-50. [PMID: 33293473 DOI: 10.18632/aging.202231] [Reference Citation Analysis]
26 Wei D, Rui B, Qingquan F, Chen C, Ping HY, Xiaoling S, Hao W, Jun G. KIF11 promotes cell proliferation via ERBB2/PI3K/AKT signaling pathway in gallbladder cancer. Int J Biol Sci 2021;17:514-26. [PMID: 33613109 DOI: 10.7150/ijbs.54074] [Reference Citation Analysis]
27 Li J, Ke J, Fang J, Chen JP. A potential prognostic marker and therapeutic target: SPOCK1 promotes the proliferation, metastasis, and apoptosis of pancreatic ductal adenocarcinoma cells. J Cell Biochem 2020;121:743-54. [PMID: 31478239 DOI: 10.1002/jcb.29320] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Qian Y, Li X, Fan R, Li Q, Zhang Y, He X, Yang W, Sun W, Lv S. MicroRNA-31 inhibits traumatic brain injury-triggered neuronal cell apoptosis by regulating hypoxia-inducible factor-1A/vascular endothelial growth factor A axis. Neuroreport 2022;33:1-12. [PMID: 34874324 DOI: 10.1097/WNR.0000000000001741] [Reference Citation Analysis]
29 Xu R, Chen Y, Wang Z, Zhang C, Dong X, Yan Y, Wang Y, Zeng Y, Chen P. Phosphoproteomics Identifies Significant Biomarkers Associated with the Proliferation and Metastasis of Prostate Cancer. Toxins (Basel) 2021;13:554. [PMID: 34437425 DOI: 10.3390/toxins13080554] [Reference Citation Analysis]
30 Chen Z, Li L, Wu W, Liu Z, Huang Y, Yang L, Luo Q, Chen J, Hou Y, Song G. Exercise protects proliferative muscle satellite cells against exhaustion via the Igfbp7-Akt-mTOR axis. Theranostics 2020;10:6448-66. [PMID: 32483463 DOI: 10.7150/thno.43577] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
31 Fan S, Yan S, Yang Y, Shang J, Hao M. Actin-Like Protein 8 Promotes the Progression of Triple-Negative Breast Cancer via Activating PI3K/AKT/mTOR Pathway. Onco Targets Ther 2021;14:2463-73. [PMID: 33883901 DOI: 10.2147/OTT.S291403] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Liu H, Liu C, Wang M, Sun D, Zhu P, Zhang P, Tan X, Shi G. Tanshinone IIA affects the malignant growth of Cholangiocarcinoma cells by inhibiting the PI3K-Akt-mTOR pathway. Sci Rep 2021;11:19268. [PMID: 34588580 DOI: 10.1038/s41598-021-98948-z] [Reference Citation Analysis]
33 Cai C, Dang W, Liu S, Huang L, Li Y, Li G, Yan S, Jiang C, Song X, Hu Y, Gu J. Anthrax toxin receptor 1/tumor endothelial marker 8 promotes gastric cancer progression through activation of the PI3K/AKT/mTOR signaling pathway. Cancer Sci. 2020;111:1132-1145. [PMID: 31977138 DOI: 10.1111/cas.14326] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
34 Chen NY, Lu K, Yuan JM, Li XJ, Gu ZY, Pan CX, Mo DL, Su GF. 3-Arylamino-quinoxaline-2-carboxamides inhibit the PI3K/Akt/mTOR signaling pathways to activate P53 and induce apoptosis. Bioorg Chem 2021;114:105101. [PMID: 34175723 DOI: 10.1016/j.bioorg.2021.105101] [Reference Citation Analysis]
35 Khezri MR, Ghasemnejad-Berenji M, Mahboubi N. The probable mechanism of reduced androgen level in COVID-19 patients. Horm Mol Biol Clin Investig 2021. [PMID: 34674407 DOI: 10.1515/hmbci-2021-0052] [Reference Citation Analysis]
36 Alotaibi MR, As Sobeai HM, Alaqil FA, Almutairi M, Alhazzani K, Sulaiman AAA, Isab AA, Hadal Alotaibi N. A newly synthesized platinum-based compound (PBC-II) increases chemosensitivity of HeLa ovarian cancer cells via inhibition of autophagy. Saudi Pharm J 2019;27:1203-9. [PMID: 31885480 DOI: 10.1016/j.jsps.2019.10.003] [Reference Citation Analysis]
37 Jing W, Li L, Zhang X, Wu S, Zhao J, Hou Q, Wu H, Ma W, Li S, Liu H, Yang B. Genetic Profiling of Breast Cancer with and Without Preexisting Metabolic Disease. Transl Oncol 2020;13:245-53. [PMID: 31869749 DOI: 10.1016/j.tranon.2019.09.008] [Reference Citation Analysis]
38 Lu X, Peng B, Chen G, Pes MG, Ribback S, Ament C, Xu H, Pal R, Rodrigues PM, Banales JM, Evert M, Calvisi DF, Chen X, Fan B, Wang J. YAP Accelerates Notch-Driven Cholangiocarcinogenesis via mTORC1 in Mice. Am J Pathol 2021;191:1651-67. [PMID: 34129844 DOI: 10.1016/j.ajpath.2021.05.017] [Reference Citation Analysis]
39 Turkes F, Carmichael J, Cunningham D, Starling N. Contemporary Tailored Oncology Treatment of Biliary Tract Cancers. Gastroenterol Res Pract 2019;2019:7698786. [PMID: 31929787 DOI: 10.1155/2019/7698786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
40 Chen J, Zhao KN, Vitetta L. Effects of Intestinal Microbial⁻Elaborated Butyrate on Oncogenic Signaling Pathways. Nutrients 2019;11:E1026. [PMID: 31067776 DOI: 10.3390/nu11051026] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 12.0] [Reference Citation Analysis]
41 Lang Q, Xiao P, Zhao M, Liang D, Meng Q, Pei T. COUP-TFII promotes metastasis and epithelial-to-mesenchymal transition through upregulating Snail in human intrahepatic cholangiocarcinoma. Acta Biochim Biophys Sin (Shanghai) 2020;52:1247-56. [PMID: 33166992 DOI: 10.1093/abbs/gmaa117] [Reference Citation Analysis]
42 Filippi R, Lombardi P, Quarà V, Fenocchio E, Aimar G, Milanesio M, Leone F, Aglietta M. Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives. Expert Opin Pharmacother 2019;20:2121-37. [PMID: 31550186 DOI: 10.1080/14656566.2019.1667335] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
43 Sun JF, Zhang D, Gao CJ, Zhang YW, Dai QS. Exosome-Mediated MiR-155 Transfer Contributes to Hepatocellular Carcinoma Cell Proliferation by Targeting PTEN. Med Sci Monit Basic Res 2019;25:218-28. [PMID: 31645540 DOI: 10.12659/MSMBR.918134] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
44 Dai J, Liu D, Chen L, Sun L. Effect of Ag-1031 on apoptosis in gastric cancer AGS cells and its effects on the PI3K/AKT/mTOR signaling pathway. Biotechnol Lett 2020;42:2447-52. [DOI: 10.1007/s10529-020-02954-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Hao XL, Gao LY, Deng XJ, Han F, Chen HQ, Jiang X, Liu WB, Wang DD, Chen JP, Cui ZH, Ao L, Cao J, Liu JY. Identification of TC2N as a novel promising suppressor of PI3K-AKT signaling in breast cancer. Cell Death Dis 2019;10:424. [PMID: 31142739 DOI: 10.1038/s41419-019-1663-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
46 Li L, Liu F, Huang W, Wang J, Wan Y, Li M, Pang Y, Yin Z. Ricolinostat (ACY-1215) inhibits VEGF expression via PI3K/AKT pathway and promotes apoptosis in osteoarthritic osteoblasts. Biomed Pharmacother 2019;118:109357. [PMID: 31548177 DOI: 10.1016/j.biopha.2019.109357] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
47 Jang DK, Lee YG, Chan Chae Y, Lee JK, Paik WH, Lee SH, Kim YT, Ryu JK. GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway. Biochem Biophys Res Commun 2020;529:1242-8. [PMID: 32819590 DOI: 10.1016/j.bbrc.2020.06.011] [Reference Citation Analysis]